Last reviewed · How we verify
Maximum androgen blockade
Maximum androgen blockade combines androgen receptor antagonists with androgen synthesis inhibitors to suppress testosterone production and block its effects in prostate cancer cells.
Maximum androgen blockade combines an androgen receptor antagonist with an androgen synthesis inhibitor to suppress testosterone production and block its effects in prostate cancer cells. Used for Metastatic prostate cancer, Advanced prostate cancer.
At a glance
| Generic name | Maximum androgen blockade |
|---|---|
| Also known as | LHRN agonist and antiandrogen |
| Sponsor | Wonju Severance Christian Hospital |
| Drug class | Androgen receptor antagonist combination therapy |
| Target | Androgen receptor; testosterone synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This therapeutic strategy uses a combination approach: an antiandrogen (such as bicalutamide or flutamide) blocks androgen receptors on cancer cells, while a gonadotropin-releasing hormone (GnRH) agonist or 5-alpha reductase inhibitor suppresses testosterone production. Together, these agents eliminate both circulating androgens and local androgen signaling, maximizing suppression of androgen-dependent prostate cancer growth.
Approved indications
- Metastatic prostate cancer
- Locally advanced prostate cancer
- High-risk localized prostate cancer (in combination with radiation therapy)
Common side effects
- Hot flashes
- Erectile dysfunction
- Gynecomastia
- Fatigue
- Decreased libido
- Weight gain
- Osteoporosis/bone loss
Key clinical trials
- PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PHASE1)
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors (PHASE3)
- Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases. (PHASE2)
- A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (PHASE1)
- Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients (PHASE4)
- A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer (PHASE1, PHASE2)
- TUPKRP Combined With MAB Therapy for LUTS/PCa (NA)
- Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maximum androgen blockade CI brief — competitive landscape report
- Maximum androgen blockade updates RSS · CI watch RSS
- Wonju Severance Christian Hospital portfolio CI